Outcomes of long term treatments of type I hereditary angioedema in a Turkish family
- PMID: 29166502
- PMCID: PMC5674698
- DOI: 10.1590/abd1806-4841.20175899
Outcomes of long term treatments of type I hereditary angioedema in a Turkish family
Abstract
Background: Hereditary angioedema is a rare autosomal dominantly inherited immunodeficiency disorder characterized by potentially life-threatening angioedema attacks.
Objective: We aimed to investigate the clinical and genetic features of a family with angioedema attacks.
Methods: The medical history, clinical features and C1-INH gene mutation of a Turkish family were investigated and outcomes of long-term treatments were described.
Results: Five members had experienced recurrent swellings on the face and extremities triggered by trauma. They were all misdiagnosed as familial Mediterranean fever (FMF) depending on frequent abdominal pain and were on colchicine therapy for a long time. They had low C4 and C1-INH protein concentrations and functions. A mutation (c.1247T>A) in C1-INH gene was detected. They were diagnosed as having hereditary angioedema with C1-INH deficiency (C1-INH hereditary angioedema) for the first time. Three of them benefited from danazol treatment without any significant adverse events and one received weekly C1 esterase replacement treatment instead of danazol since she had a medical history of thromboembolic stroke.
Study limitations: Small sample size of participants.
Conclusion: Patients with C1-INH hereditary angioedema may be misdiagnosed as having familial Mediterranean fever in regions where the disorder is endemic. Medical history, suspicion of hereditary angioedema and laboratory evaluations of patients and their family members lead the correct diagnoses of hereditary angioedema. Danazol and C1 replacement treatments provide significant reduction in hereditary angioedema attacks.
Conflict of interest statement
Conflict of interest: None
Figures

Similar articles
-
C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis.Transfusion. 2009 Sep;49(9):1987-95. doi: 10.1111/j.1537-2995.2009.02230.x. Epub 2009 May 20. Transfusion. 2009. PMID: 19497056 Clinical Trial.
-
Hereditary angioedema with normal c1 inhibition.Curr Allergy Asthma Rep. 2009 Jul;9(4):280-5. doi: 10.1007/s11882-009-0039-9. Curr Allergy Asthma Rep. 2009. PMID: 19656474
-
[Effect of danazol treatment on growth in pediatric patients with hereditary angioedema due to C1-inhibitor deficiency].Orv Hetil. 2017 Aug;158(32):1269-1276. doi: 10.1556/650.2017.30806. Orv Hetil. 2017. PMID: 28780879 Hungarian.
-
Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology.Adv Ther. 2023 Mar;40(3):814-827. doi: 10.1007/s12325-022-02401-0. Epub 2023 Jan 7. Adv Ther. 2023. PMID: 36609679 Free PMC article. Review.
-
Treatment of Hereditary Angioedema.J Investig Allergol Clin Immunol. 2021 Feb;31(1):1-16. doi: 10.18176/jiaci.0653. J Investig Allergol Clin Immunol. 2021. PMID: 33602658 Review.
References
-
- Kesim B, Uyguner ZO, Gelincik A, Mete Gökmen N, Sin AZ, Karakaya G, et al. The Turkish Hereditary Angioedema Pilot Study (TURHAPS): the first Turkish series of hereditary angioedema. Int Arch Allergy Immunol. 2011;156:443–450. - PubMed
-
- Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69:602–616. - PubMed
-
- Kalmár L, Hegedüs T, Farkas H, Nagy M, Tordai A. HAEdb: a novel interactive,locus-specific mutation database for the C1 inhibitor gene. Hum Mutat. 2005;25:1–5. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous